Cancer and clinical oncology最新文献_第6页

Angiomatoid Fibrous Histiocytoma in the Forearm: A Case Report 前臂血管瘤样纤维组织细胞瘤1例报告

Cancer and clinical oncology Pub Date : 2016-01-07 DOI: 10.5539/CCO.V6N1P36

H. M. Alshareef, Ahmed H Alhasan, Mohammed G. Felemban, A. Almalki, Amer Mohammed A Alshareef

{"title":"Angiomatoid Fibrous Histiocytoma in the Forearm: A Case Report","authors":"H. M. Alshareef, Ahmed H Alhasan, Mohammed G. Felemban, A. Almalki, Amer Mohammed A Alshareef","doi":"10.5539/CCO.V6N1P36","DOIUrl":"https://doi.org/10.5539/CCO.V6N1P36","url":null,"abstract":"Background: Angiomatoid fibrous histiocytoma [AFH] is a rare soft tissue tumor most commonly occurring in children, adolescents, and young adults. It is considered to be a tumor of intermediate malignancy because of its less aggressive course. The extremities are the most common site of involvement, followed by the trunk and head and neck. Case presentation: A 28-Year-old male presented with a right forearm mass that has been present for 2 years. There was no associated fever, no trauma, no night pain and no constitutional symptoms. On examination he had a forearm mass dorsally measuring 2x3 cm, firm, rounded, mobile with no skin changes and full range motion joint above and joint below. Lab and imaging studies done which showed soft tissue mass, multilobulated complex heterogeneous with increased vascularity. Patient underwent biopsy and surgical excision. Conclusion: Angiomatoid fibrous histiocytoma is a neoplasm of intermediate biologic potential. Most often, the extremities are the most common site of involvement, followed by the trunk and head and neck of children and young adults. Its rarity may lead to misdiagnosis as either a reactive lesion or a benign or higher-grade tumor. This tumor has a relatively rare metastasis and its overall clinical outcome is excellent. It is clinically important to accurately diagnose this tumor so that wide local excision may be performed and patients may be appropriately monitored and followed up.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"35 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2016-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70723484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Colorectal Cancer Survival Disparities among Puerto Rican Hispanics: A Comparison to Racial/Ethnic Groups in the United States. 波多黎各拉美裔人结直肠癌癌症生存率差异：与美国种族/民族群体的比较。

Cancer and clinical oncology Pub Date : 2016-01-01 Epub Date: 2016-08-24 DOI: 10.5539/cco.v5n2p29

Maria Gonzalez-Pons, Mariela Torres, Javier Perez, Anneliese Velez, Jean Pierre Betancourt, Lorena Marcano, Marievelisse Soto-Salgado, Marcia Cruz-Correa

{"title":"Colorectal Cancer Survival Disparities among Puerto Rican Hispanics: A Comparison to Racial/Ethnic Groups in the United States.","authors":"Maria Gonzalez-Pons, Mariela Torres, Javier Perez, Anneliese Velez, Jean Pierre Betancourt, Lorena Marcano, Marievelisse Soto-Salgado, Marcia Cruz-Correa","doi":"10.5539/cco.v5n2p29","DOIUrl":"10.5539/cco.v5n2p29","url":null,"abstract":"Purpose: Ethnic/racial disparities in colorectal cancer (CRC) survival have been well documented. However, there is limited information regarding CRC survival among Hispanic subgroups. This study reports the 5-year relative survival of Puerto Rican Hispanic (PRH) CRC patients and the relative risk of death compared to other racial/ethnic groups in the US.Methods: CRC incidence data from subjects ≥50 years was obtained from the Puerto Rico Central Cancer Registry and the Surveillance, Epidemiology and End Results (SEER) database from January 1, 2001 to December 31, 2003. Relative survival rates were calculated using the life tables from the population of PR and SEER. A Poisson regression model was used to assess relative risk of death by stage, sex, and age.Results: A total of 76,444 subjects with incident CRC were analyzed (non-Hispanic White (NHW) n=59,686; non-Hispanic black (NHB) n=7,700; US Hispanics (USH) n=5,699; PRH n=3,359). Overall and stage-specific five-year survival rates differed by race/ethnicity. When comparing PRH to the other racial/ethnic groups, PRH had the lowest survival rates in regional cancers and were the only racial/ethnic group where a marked 5-year survival advantage was observed among females (66.0%) compared to males (60.3%). A comparable and significantly higher relative risk of death of CRC was observed for PRH and NHB compared to NHW.Conclusions: Our findings establish baseline CRC survival data for PRH living in Puerto Rico. The gender and racial/ethnic disparities observed in PRH compared to US mainland racial/ethnic groups warrant further investigation of the risk factors affecting this Hispanic subgroup.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"5 2","pages":"29-37"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342562/pdf/nihms-997584.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36895194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges of Preoperative Diagnosis and Management of Scalene Intramuscular Angioma 斜角肌内血管瘤术前诊断与治疗的挑战

Cancer and clinical oncology Pub Date : 2015-12-18 DOI: 10.5539/CCO.V5N1P20

Lei Zhang, B. Wang, J. Goddard

{"title":"Challenges of Preoperative Diagnosis and Management of Scalene Intramuscular Angioma","authors":"Lei Zhang, B. Wang, J. Goddard","doi":"10.5539/CCO.V5N1P20","DOIUrl":"https://doi.org/10.5539/CCO.V5N1P20","url":null,"abstract":"Intramuscular angioma of scalene muscle is rare with only five cases reported so far. Four of them have not been suspected before surgery; one was diagnosed preoperatively by core biopsy. Preoperative diagnosis is important for management. Awareness of cytologic features could help preoperative diagnosis when need of ruling out malignancy and coagulopathy make fine needle aspiration a choice. We herein demonstrate a new case of a 27 year old male with history of hepatocellular carcinoma, who presented with a 6 cm left supraclavicular mass. The fine needle aspiration was paucicellular; however, the bland ovoid to spindle cells with a whirling and luminal arrangement in the background of blood, fatty drops and degenerate muscle are suggestive of intramuscular angioma. The magnetic resonance imagines (MRI) demonstrate a T1 isointense and T2 hyperintense ill-defined lesion splaying anterior and mid scalene muscles with subtle vascular voids at periphery. These features in combination with cytology findings indicate intramuscular angioma. The pre-operative findings are correlated to the histologic picture of mixed capillaries and varying sized venues intervening with fatty tissue and atrophic muscle. Intraoperatively, the mass is adjacent to the brachial plexus rootlets, interdigitating with the scalene muscle and pushing the carotid sheath, left subclavicular artery and vein aside. Following embolization, the mass is resected with minimal bleeding. Our case suggests that scalene intramuscular angioma can be successfully managed by surgery after embolization; preoperative diagnosis rendered by cytologic features and imaging characters would aid the planning of surgery.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"5 1","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2015-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V5N1P20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin Cancer and Its Correlates: A Study of Knowledge and Preventive Behavior in Riyadh 皮肤癌及其相关因素:利雅得居民的知识和预防行为研究

Cancer and clinical oncology Pub Date : 2015-12-08 DOI: 10.5539/CCO.V5N1P11

Fahad Alamri, M. Y. Saeedi, Muslet H. Alharbi, A. Ali, A. Ibrahim, K. Kassim

{"title":"Skin Cancer and Its Correlates: A Study of Knowledge and Preventive Behavior in Riyadh","authors":"Fahad Alamri, M. Y. Saeedi, Muslet H. Alharbi, A. Ali, A. Ibrahim, K. Kassim","doi":"10.5539/CCO.V5N1P11","DOIUrl":"https://doi.org/10.5539/CCO.V5N1P11","url":null,"abstract":"Background: Worldwide, the incidence of skin cancer has increased due to increased UV exposure to solar and artificial sources. In Saudi Arabia, skin cancer ranked the 9 th most common cancer for both sexes. However, it is considered to be a preventable disease. WHO has proposed several preventive methods to avoid the damaging effects of excessive exposure to UV rays including; social education and adopting positive behavioral changes. The present study aimed to evaluate the level of knowledge, attitudes and behaviors of people in Riyadh city towards skin cancer. Results: The mean respondent's age was 35 years (12-65 years). Females represented about two-thirds of the 341 respondent. A statistically significant associations were detected between awareness about skin cancer with the age (Beta =0.03, p =0.047), educational level (Beta =0.63, p =0.042) and skin color (Beta =-2.14, p<0.001) being significant predictors for disease. Conclusions: To our knowledge, this was the first study to assess the level of knowledge, attitudes, and practices regarding skin cancer in Saudi Arabia. Despite the limitations, the present study’s findings suggested that Saudis lack the sufficient knowledge to understand and assess the importance of skin cancer risk. In addition, the level of knowledge, attitude and behaviors are influenced by several factors as age, education level and skin color.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"5 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2015-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V5N1P11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Non–Hodgkin’s Lymphoma of the Appendix 阑尾非霍奇金淋巴瘤

Cancer and clinical oncology Pub Date : 2015-12-07 DOI: 10.5539/CCO.V5N1P1

G. Watson, J. Gleeson, D. Kelly, D. Byrne, P. D. L. Harpe-Golden, J. Mulsow, A. Fortune, D. Carney

引用次数: 2

Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes. 甲基化标记在滤泡性甲状腺癌亚型早期检测和分化中的应用。

Cancer and clinical oncology Pub Date : 2015-11-01 Epub Date: 2015-06-15 DOI: 10.5539/cco.v4n2p1

Josena K Stephen, Kang Mei Chen, Jason Merritt, Dhananjay Chitale, George Divine, Maria J Worsham

{"title":"Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes.","authors":"Josena K Stephen, Kang Mei Chen, Jason Merritt, Dhananjay Chitale, George Divine, Maria J Worsham","doi":"10.5539/cco.v4n2p1","DOIUrl":"https://doi.org/10.5539/cco.v4n2p1","url":null,"abstract":"Thyroid cancer has the fastest rising incidence rates and is the fifth most common cancer in women. There are four main types of which the papillary and follicular types together account for >90%, followed by medullary cancers (3%-5%) and anaplastic carcinomas (<3%). For individuals who present with early stage disease of papillary and follicular cancers, there are no accurate markers to predict whether they will develop metastatic or recurrent disease. Our immediate goal is to molecularly differentiate follicular cancer subtypes for enhanced classification. Promoter methylation status of genes with reported associations in thyroid cancer (CASP8, CDKN2A, DAPK1, ESR1, NIS, RASSF1 and TIMP3) were examined in a cohort of follicular thyroid cancers comprising of 26 Hurthle and 27 Classic subtypes utilizing quantitative methylation-specific PCR. RASSF1 was differentially methylated in Classic tumor tissue compared to Hurthle (p<0.001). Methylation of RASSF1 pointed to racial group differences between African Americans and Caucasian Americans (p=0.05). Extra thyroidal extension was found to be associated with DAPK1 (p=0.014) and ESR1 (p=0.036) methylation. Late stage disease was associated with older age (p<0.001) and methylation of DAPK1 (p=0.034) and ESR1 (p=0.035). The methylation status of RASSF1, DAPK1 and ESR1 suggests the utility of methylation markers to molecularly differentiate thyroid cancer subtypes for enhanced classification and early detection of thyroid cancer.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 2","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/cco.v4n2p1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34380117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Exacerbation of Migraines Following Robotic Surgery for Endometrial Carcinoma 子宫内膜癌机器人手术后偏头痛加重

Cancer and clinical oncology Pub Date : 2015-10-22 DOI: 10.5539/CCO.V4N2P53

J. P. Geisler, K. Manahan

引用次数: 0

Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy 抗肿瘤药物治疗后存活11年的复发性典型胶质母细胞瘤患者的综合基因组分析

Cancer and clinical oncology Pub Date : 2015-10-22 DOI: 10.5539/CCO.V4N2P41

S. Burzynski, T. Janicki, Gregory S. Burzynski

{"title":"Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy","authors":"S. Burzynski, T. Janicki, Gregory S. Burzynski","doi":"10.5539/CCO.V4N2P41","DOIUrl":"https://doi.org/10.5539/CCO.V4N2P41","url":null,"abstract":"Most patients with recurrent glioblastoma (RGBM) die within 6 months regardless of treatment. In phase II studies of Antineoplaston A10 and AS2-1 injections (ANP), our investigators have reported objective responses and long-term survival in RGBM. Using a next-generation sequencing (NGS) based assay of 343 cancer-related genes and introns, comprehensive genomic profiling of tumor tissue obtained from a RGBM patient (who remains alive and well) was performed 11 years after diagnosis and permitted assignment of the patient’s RGBM to the classical subgroup. The most important genomic alterations included amplification of epidermal growth factor receptor (EGFR), cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A/B), loss of phosphatase and tensin homolog (PTEN) and telomerase reverse transcriptase (TERT) mutation. An analysis of the signaling networks and other targets of ANP therapy was recently performed and presented in this publication. Based on our findings, patients with classical RGBM have a reasonable possibility of responding to ANP therapy and experiencing long-term survival. It is proposed that this subgroup of RGBM patients be enrolled in a genomics-driven clinical trial of ANP therapy.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"41"},"PeriodicalIF":0.0,"publicationDate":"2015-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N2P41","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Anal Cancer Patients in a Metropolitan Hospital Present Infection with Multiple Oncogenic Viruses 某都市医院肛门癌患者存在多种致瘤病毒感染

Cancer and clinical oncology Pub Date : 2015-08-03 DOI: 10.5539/CCO.V4N2P32

Kenneth O. Simbiri, H. Jha, D. Henry, E. Robertson

引用次数: 1

A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients With Recurrent Anaplastic Astrocytoma—Final report (Protocol BT-15) 抗瘤质体A10和AS2-1注射治疗复发性间变性星形细胞瘤的II期研究——最终报告(方案BT-15)

Cancer and clinical oncology Pub Date : 2015-06-17 DOI: 10.5539/CCO.V4N2P13

S. Burzynski, T. Janicki, Gregory S. Burzynski

{"title":"A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients With Recurrent Anaplastic Astrocytoma—Final report (Protocol BT-15)","authors":"S. Burzynski, T. Janicki, Gregory S. Burzynski","doi":"10.5539/CCO.V4N2P13","DOIUrl":"https://doi.org/10.5539/CCO.V4N2P13","url":null,"abstract":"The recommended treatment for recurrent anaplastic astrocytoma (AA) consists of chemotherapy with temozolomide. There is an urgent need for new therapies for such patients. This phase II study evaluates efficacy and safety of a different form of cancer therapy that consists of antineoplastons A10 and AS2-1 (ANP). 27 patients, ages 19 to 57 years (median, 41) with recurrent AA were treated. All patients previously underwent surgery, all received radiation therapy, and 16 underwent chemotherapy. The patients received treatment with ANP administered daily every four hours (median dose of A10 6.0 g/kg/d and AS2-1 0.25 g/kg/d). All patients were included in efficacy and safety analysis. The median duration of ANP was 23.1 weeks. A complete response was documented in 7%, partial response in 11%, and stable disease in 22% of patients. Progression-free survival and overall survival at 12 months was 26% and 41% respectively. The only serious toxicity was Grade 3 reversible hypokalemia in 7% of patients. There was no chronic toxicity and there was a high quality of life. ANP shows efficacy with very good toxicity profile in this cohort of patients with recurrent AA.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2015-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N2P13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8